Clinical Trial Update: Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of incobotulinum toxin for trigeminal neuralgia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• Incobotulinum toxin (incobotulinumtoxinA)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Trigeminal Neuralgia | Phase 2 | Status: TERMINATED | Results posted: 2023-06-28